Aurinia preliminary Q4 net product revenue $42M (+49% YoY); FY23 $159M; guides FY24 $200-220M

Aurinia Pharmaceuticals Inc.

2023-FY EPS reported -$0.54 revenue$175,513,000

Preliminary net product revenue Q4 2023: ~$42M, up 49% YoY from $28.3M; full-year ~$159M, up 53% from $103.5M.
Total revenue Q4: ~$45M (+59% YoY); full-year ~$176M (+31% YoY); cash & investments ~$351M at year-end.
Guides 2024 net product revenue $200-220M; targets cash flow positive in H2 2024.
Patients on LUPKYNIS therapy: ~2,066 at Dec 31, 2023, up from 1,525 a year earlier; 438 PSFs added in Q4.
Strategic review process ongoing; no further updates on potential sale or merger at this time.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aurinia Pharmaceuticals Inc. reported fourth quarter and full-year 2023 results: revenue approximately $45 million and $176 million. Guidance initiated.

Period: fourth quarter and full-year 2023
Revenue: approximately $45 million and $176 million
Guidance: initiated
Result: preliminary results

Exact text from the filing

AURINIA PROVIDES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL-YEAR 2023 NET REVENUE RESULTS Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million

View on SEC.gov

35 earnings releases filed in the last 30 days. Browse all earnings releases →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-24-000001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.